Related Experiment Video

Updated: Jul 5, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
03:22

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases

Published on: March 1, 2024

Treatment of community-acquired pneumonia, with special emphasis on gemifloxacin

Serkan Oncü1

  • 1Adnan Menderes University Medical Faculty, Department of Infectious Diseases and Clinical Microbiology Aydin, Turkey.

Therapeutics and Clinical Risk Management
|May 20, 2008
PubMed

Insights

Community-acquired pneumonia (CAP) treatment depends on risk factors. Gemifloxacin offers broad-spectrum activity against resistant strains, making it an excellent choice for CAP management.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Pulmonology

Background:

  • Community-acquired pneumonia (CAP) presents a significant global health challenge, contributing to high rates of illness, death, and healthcare resource use.
  • Effective CAP antimicrobial selection necessitates careful patient assessment, considering risk factors like prior antibiotic exposure and comorbidities.

Purpose of the Study:

  • To evaluate the role of newer-generation quinolones, specifically gemifloxacin, in the empirical treatment of community-acquired pneumonia.
  • To highlight gemifloxacin's in vitro activity, pharmacokinetic/pharmacodynamic properties, and safety profile as a treatment option for CAP.

Main Methods:

  • Review of in vitro antimicrobial activity against common CAP pathogens.
  • Analysis of pharmacokinetic and pharmacodynamic data for newer-generation quinolones.
  • Evaluation of clinical data and safety profiles for gemifloxacin in CAP treatment.

Main Results:

  • Narrow-spectrum agents like amoxicillin or macrolides are suitable for patients without risk factors.
  • Broader-spectrum agents are recommended for patients with risk factors.
  • Gemifloxacin demonstrates superior in vitro activity against susceptible and resistant CAP pathogens compared to other quinolones.

Conclusions:

  • Gemifloxacin's enhanced bioavailability, pharmacokinetic/pharmacodynamic profile, and safety make it a highly effective option for empirical CAP therapy.
  • The choice of antimicrobial for CAP should be guided by patient-specific risk factors.
  • Newer-generation quinolones, particularly gemifloxacin, represent valuable tools in combating resistant CAP strains.
Keywords:
community-acquired pneumoniagemifloxacintreatment

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...